Walmart Inc. (NYSE: WMT) has rarely wavered from founder Sam Walton's gospel of Christian free enterprise or his conservatism.
So it should come as no surprise that, over the years, the world's largest retailer has taken stands against medical marijuana laws, sometimes refusing to cover employees' legal cannabis prescriptions.
So the most recent news coming out of Bentonville, Ark., was a bit shocking.
Earlier this week, Walmart's Canadian division said it's exploring the possibility of selling cannabis-infused products in its stores.
While various global beverage and tobacco giants have been showing interest in the legal cannabis market, Walmart is the first big retailer do so – and probably the most surprising choice possible.
What's next? Cannabis grow kits at Hobby Lobby? Marijuana-infused nuggets at Chick-fil-A?
Even more jaw-dropping is that this, technically, isn't Walmart's first foray into pot.
Earlier this year, it greenlit the sale of American Cannabis Co. Inc. (OTC: AMMJ) soil mix via its online store. While this is a far cry from stocking Walmart shelves with buds and edibles, it was a big step into the cannabis market for the traditionally conservative retailer.
Now, Walmart doesn't want to anger conservative customers. That's why you won't be able to buy your bud from the retailer – in Canada or here at home – maybe ever.
Instead, Walmart Canada is looking into cannabidiol, or CBD.
Critical Update: You’re Invited to the First-Ever National Event for Cannabis Investors. Click Here to Register for This Free Online Event…
CBD is a non-psychoactive but beneficial agent in marijuana. One CBD drug – a childhood epilepsy treatment from GW Pharmaceuticals Plc. (Nasdaq: GWPH) – just got reclassified as a Schedule V drug in the United States, on par with cough syrup.
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
While Walmart Canada execs have stated, "We do not have plans to carry CBD products at this time," they do admit to some preliminary fact finding. And that means Canadians soon may be able to pick up CBD-infused products – from face creams to coffee drinks – at their local Walmart.
Of course, this is a balancing act for Walmart. While they don't want to offend their conservative customers, Genesis Market Insights recently valued the global legal marijuana market at $17.18 billion. By 2023, it's expected to reach $59 billion.
Those are profits Walmart doesn't want to miss out on.
And neither do investors...
With Canada going fully legal this Wednesday, Oct. 17, it seems like every company is trying to get in on the $22.6 billion windfall that Deloitte's been forecasting.
With a market this saturated, companies will fail, and you're not going to want to put your money into one of the "tiny pot stocks" that never makes it off the ground.
However, I have a proprietary set of tools in my corner that helped me find the big winners. With 35 years of investing under my belt, I've developed strategies that are virtually foolproof. I've delivered more than 44 double- and triple-digit cannabis winners to my readers in just over two years.
And Canada's legalization will produce even more big winners. They could make you a millionaire – no, a multimillionaire – by this time next year. I'm talking gains of 46,000%.
After all, even Walmart's jumping in.
America’s Great Green Gold Rush Is Just Getting Started
We stand at the forefront of an unstoppable economic revolution. It’s a new gold rush – a green gold rush. And it’s just getting started.
That’s why we’ve gathered two of the leading members of America’s cannabis revolution for an exclusive, first-of-its-kind event.
Together, former Speaker of the House John Boehner and Danny Brody, the architect behind two of the largest cannabis IPOs in history, will show you why they are “all in” on this burgeoning sector and why every serious investor should be, too.
Just click here to claim your seat at this free online event.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.